Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 582.38 Mil Enterprise Value: 351.37 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc at World Muscle Society 2023 Data Update Transcript

Oct 03, 2023 / 08:30PM GMT
Release Date Price: €15.2 (-1.94%)
Operator

Thank you for standing by, and welcome to REGENXBIO RGX-202 Interim Data Call. (Operator Instructions) I would now like to hand the call over to President and CEO, Ken Mills. Please go ahead.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Hello. Good afternoon, everyone. This is Ken. If you're joining through the webcast, there are slides available, and they are self-guided. If you're joining on the phone, the slides are available on the Investors section of our website.

I'm going to start on Slide 2. Thanks for joining the call today. I'm very excited, so we'll get right into it. We have 2 updates today. First, we're reporting an update on patients dosed with RGX-202 from dose level 1 of our AFFINITY DUCHENNE study. This update will be presented at the World Muscle Society Conference in Charleston, South Carolina this week. Compared to our last update in July, this will include additional patient longer-term follow-up safety and first measures of RGX-202 microdystrophin expression from patient biopsies that are collected at 3 months.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot